Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor

被引：0
|
作者：
Surya P. Ayalasomayajula
Thomas H. Langenickel
Pierre Jordaan
Wei Zhou
Priyamvada Chandra
Diego Albrecht
Parasar Pal
Iris Rajman
Gangadhar Sunkara
机构：
[1] Novartis Institutes for BioMedical Research,Drug Metabolism and Pharmacokinetics
[2] Novartis Pharma AG,Translational Medicine, Clinical Pharmacology and Profiling
[3] Novartis Healthcare Pvt Ltd,undefined
来源：
European Journal of Clinical Pharmacology | 2016年 / 72卷
关键词：
Angiotensin receptor neprilysin inhibitor; LCZ696; Pharmacokinetics; Renal impairment; Valsartan; Sacubitril;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1065 / 1073
页数：8
相关论文
共 50 条
  • [41] The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
    Chen, Yan
    He, Qian
    Mo, Dun-Chang
    Chen, Long
    Lu, Jia-Lu
    Li, Rui-Xing
    Huang, Jie
    MEDICINE, 2022, 101 (41) : E30904
  • [42] A metabolomics approach to profiling the cardioprotective effect of LCZ696, an angiotensin receptor-neprilysin inhibitor, on ischemia induced heart failure
    Xia, Yan
    Chen, Zhangwei
    Chen, Ao
    Lu, Danbo
    Jia, Jianguo
    Zou, Yunzeng
    Qian, Juying
    Ge, Junbo
    RSC ADVANCES, 2017, 7 (46) : 29170 - 29183
  • [43] Effect of the angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril according to systolic blood pressure in PARADIGM-HF
    Bohm, M.
    Refsgaard, J.
    Ramires, F. J. A.
    Rouleau, J. L.
    Solomon, S. D.
    Swedberg, K.
    Zile, M.
    Shi, V. C.
    Packer, M.
    Mcmurray, J. J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 393 - 393
  • [44] Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
    Dargad, Ramesh R.
    Prajapati, Mahesh R.
    Dargad, Rohit R.
    Parekh, Jai D.
    INDIAN HEART JOURNAL, 2018, 70 : S102 - S110
  • [45] LCZ696 ( Valsartan/Sacubitril) - A Possible New Treatment for Hypertension and Heart Failure
    Andersen, Mathilde Borring
    Simonsen, Ulf
    Wehland, Markus
    Pietsch, Jessica
    Grimm, Daniela
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 118 (01) : 14 - 22
  • [46] LCZ696, the First-in-Class Angiotensin Receptor Neprilysin Inhibitor, Improves Vascular Reactivity in the Setting of Heart Failure
    Trivedi, Rishi K.
    Li, Zhen
    Polhemus, David J.
    Yoo, Daniel
    Koiwaya, Hiroshi
    Goodchild, Traci T.
    Lefer, David J.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2017, 112 : 162 - 162
  • [47] The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats
    Rahman, Asadur
    Sherajee, Shamshad J.
    Rafiq, Kazi
    Kobara, Hideki
    Masaki, Tsutomu
    Nakano, Daisuke
    Morikawa, Takashi
    Konishi, Yoshio
    Imanishi, Masahito
    Nishiyama, Akira
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2020, 142 (03) : 124 - 126
  • [48] LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Increases Nitric Oxide Bioavailability and Improves Vascular Function in Ischemic Heart Failure
    Trivedi, Rishi K.
    Li, Zhen
    Polhemus, David J.
    Yoo, Daniel
    Koiwaya, Hiroshi
    Goodchild, Traci T.
    Lefer, David J.
    CIRCULATION, 2017, 136
  • [49] Effect of LCZ696 and Its Components Sacubitril and Valsartan on Insulin Secretion and Glucose Homeostasis in Mice
    Esser, Nathalie
    Schmidt, Christine R.
    Barrow, Breanne
    Cronic, Laura
    Hackney, Daryl J.
    Mongovin, Steve M.
    Hull, Rebecca L.
    Zraika, Sakeneh
    DIABETES, 2020, 69
  • [50] The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects
    Langenickel, Thomas H.
    Tsubouchi, Chiaki
    Ayalasomayajula, Surya
    Pal, Parasar
    Valentin, Marie-Anne
    Hinder, Markus
    Jhee, Stanford
    Gevorkyan, Hakop
    Rajman, Iris
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (05) : 878 - 890
12345